Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alacrita and Debiopharm Group™ Collaborate

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Collaboration to identify early stage drug candidates from the Massachusetts life science cluster.

Alacrita and Debiopharm Group™ (Debiopharm) have established an alliance to identify oncological, autoimmune, infectious diseases as well as metabolic in-licensing opportunities stemming from the Massachusetts life science cluster.

Alacrita will strengthen Debiopharm’s in-house scouting team in their search for small molecules, antibody or peptide-based product candidates.

The companies are seeking preclinical assets against novel targets which represent first-in-class opportunities.

Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company recently in-licensed assets from two Massachusetts companies, including Mercury Therapeutics Inc. (Woburn, MA) and Curis Inc. (Lexington, MA).

In recognition of the depth and breadth of life science innovation in Massachusetts, Debiopharm sees the value of a local presence in the region and has selected Alacrita as its representative.

Alacrita is also in charge of identifying opportunities for Debiopharm elsewhere on the East Coast.

David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: “Massachusetts hosts global leaders in pharmaceutical innovation. As such, the area represents a strategic priority for us as we source opportunities from around the world to expand our pipeline of novel medicines. We are delighted to be working with Alacrita, a leading pharma consultancy on both sides of the Atlantic.”

Rob Johnson, Partner at Alacrita Consulting, said: “Debiopharm’s resources and expertise in global pharmaceutical development make it an ideal partner for Massachusetts organizations looking to move their preclinical programs into clinical trials. Debiopharm has a track record of shepherding early stage pharmaceutical programs into late stage clinical trials and has demonstrated extraordinary success in delivering new medical breakthroughs to patients, a testament to its impressive preclinical, clinical, manufacturing, drug delivery, formulation and regulatory expertise. Alacrita is proud to have been selected by Debiopharm to source new in-licensing opportunities for the group and enable the next generation of medical products.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alacrita Aggregates the Life Science Practices of Two Consulting Firms
Company appoints Simon Turner PhD FRSC as Partner.
Friday, May 10, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!